ATE552503T1 - Ctgf als biomarker, therapeutisches und diagnostisches ziel - Google Patents
Ctgf als biomarker, therapeutisches und diagnostisches zielInfo
- Publication number
- ATE552503T1 ATE552503T1 AT07818669T AT07818669T ATE552503T1 AT E552503 T1 ATE552503 T1 AT E552503T1 AT 07818669 T AT07818669 T AT 07818669T AT 07818669 T AT07818669 T AT 07818669T AT E552503 T1 ATE552503 T1 AT E552503T1
- Authority
- AT
- Austria
- Prior art keywords
- ctgf
- diseases
- biomarrker
- therapeutic
- diagnostic target
- Prior art date
Links
- 102100031168 CCN family member 2 Human genes 0.000 title abstract 4
- 101000777550 Homo sapiens CCN family member 2 Proteins 0.000 title abstract 4
- 230000001225 therapeutic effect Effects 0.000 title 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 208000014951 hematologic disease Diseases 0.000 abstract 3
- 238000003556 assay Methods 0.000 abstract 1
- 239000000090 biomarker Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/06—Gastro-intestinal diseases
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/12—Pulmonary diseases
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/22—Haematology
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/34—Genitourinary disorders
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Pathology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyrrole Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06021596 | 2006-10-16 | ||
| PCT/EP2007/008590 WO2008046517A1 (en) | 2006-10-16 | 2007-10-04 | Ctgf as a biomarker, therapeutic and diagnostic target |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE552503T1 true ATE552503T1 (de) | 2012-04-15 |
Family
ID=38895778
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT07818669T ATE552503T1 (de) | 2006-10-16 | 2007-10-04 | Ctgf als biomarker, therapeutisches und diagnostisches ziel |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20110111394A1 (de) |
| EP (1) | EP2074429B1 (de) |
| AT (1) | ATE552503T1 (de) |
| ES (1) | ES2383235T3 (de) |
| WO (1) | WO2008046517A1 (de) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ601660A (en) | 2008-08-25 | 2014-05-30 | Excaliard Pharmaceuticals Inc | Antisense oligonucleotides directed against connective tissue growth factor and uses thereof |
| KR101187814B1 (ko) | 2010-03-22 | 2012-10-08 | 광주과학기술원 | 심부전 예방 또는 치료용 약제학적 조성물 및 심부전 예방 또는 치료제의 스크리닝 방법 |
| US11340237B2 (en) | 2016-09-16 | 2022-05-24 | Takeda Pharmaceutical Company Limited | Metabolite biomarkers for diseases associated with the contact activation system |
| WO2018149929A1 (en) * | 2017-02-16 | 2018-08-23 | Bayer Pharma Aktiengesellschaft | Combination of reporter gene assays and transcriptional analysis |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE485834T1 (de) | 1998-09-08 | 2010-11-15 | Ford Henry Health System | Verfahren zum nachweis von bindegewebswachstumsfaktor zur diagnose von nierkrankheiten |
| US20030113816A1 (en) | 2001-09-18 | 2003-06-19 | Weitz Stephen L. | Methods of assaying connective tissue growth factor |
| EP1720562A4 (de) | 2004-01-15 | 2009-10-28 | Scios Inc | Verfahren zur behandlung von kardialer remodellierung nach myokardschädigung |
-
2007
- 2007-10-04 ES ES07818669T patent/ES2383235T3/es active Active
- 2007-10-04 US US12/445,737 patent/US20110111394A1/en not_active Abandoned
- 2007-10-04 AT AT07818669T patent/ATE552503T1/de active
- 2007-10-04 EP EP07818669A patent/EP2074429B1/de not_active Not-in-force
- 2007-10-04 WO PCT/EP2007/008590 patent/WO2008046517A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| EP2074429A1 (de) | 2009-07-01 |
| EP2074429B1 (de) | 2012-04-04 |
| ES2383235T3 (es) | 2012-06-19 |
| WO2008046517A1 (en) | 2008-04-24 |
| US20110111394A1 (en) | 2011-05-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2008046509A8 (en) | Ltbp2 as a biomarker, therapeutic and diagnostic target | |
| ATE449097T1 (de) | Pyridoä2,3-düpyrimidin-2,4-diamin-verbindungen als ptpib-hemmer | |
| WO2009038689A3 (en) | Compositions and methods for diagnosis and treatment of type 2 diabetes | |
| WO2007070359A3 (en) | Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, and compositions, and uses thereof | |
| CL2007003341A1 (es) | Compuestos derivados de imidazotriazinas; composicion farmaceutica, util para el tratamiento del cancer, arteroesclerosis y enfermedades cardiovasculares entre otras. | |
| EA200901166A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr 119 | |
| EA200802428A1 (ru) | Комбинации агентов для биологической борьбы и нематоцидов, входящих в покрытие семян | |
| DE602007009095D1 (de) | Tetrahydropyrrolopyrimidindione und ihre verwendung als inhibitoren der humanen neutrophilen elastase | |
| WO2008070129A3 (en) | Compositions and methods for the treatment of inflammatory disease | |
| WO2008030273A3 (en) | Compositions and methods for diagnosis and treatment of type 2 diabetes | |
| MX2009000285A (es) | Piperidinas sustituidas que incrementan la actividad de p53 y usos de las mismas. | |
| WO2011002834A3 (en) | Compositions and methods for diagnosis and treatment of type 1 diabetes | |
| CL2008000531A1 (es) | Compuestos derivados de heterociclos, inhibidores de la aspartilproteasa; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de enfermedades cardiovasculares, cognitivas y neurodegenerativas tales como la enfermeda | |
| ATE554091T1 (de) | Aminotetrahydropyrane als dipeptidylpeptidase-iv- inhibitoren zur behandlung oder prävention von diabetes | |
| EA201300242A1 (ru) | Фармацевтические композиции, содержащие замещенные ациланилиды | |
| BR112012027034A2 (pt) | inibidores da arginase e suas aplicações terapêuticas | |
| EA201200323A1 (ru) | Соединения и композиции, как ингибиторы протеинкиназы | |
| WO2007095601A3 (en) | Novel acetyl-coa carboxylase (acc) inhibitors and their use in diabetes, obesity and metabolic syndrome | |
| ECSP088745A (es) | Derivados sustituidos de cromanol y su uso | |
| MA31435B1 (fr) | Inhibition de metastases tumorales par des anticoprs anti-neuropiline 2 | |
| WO2008112290A3 (en) | Use of ephb4 as a diagnostic marker and a therapeutic target for ovarian cancer | |
| WO2007109107A3 (en) | Atf4 as a therapeutic target in alzheimers disease and other neurological disorders | |
| EA200900261A1 (ru) | Применение эсцина | |
| BRPI0519919A2 (pt) | composições farmacêuticas compreendendo inibidores da nep, inibidores do sistema de produção de endotelina endógena e inibidores da hmg coa redutase | |
| ATE552503T1 (de) | Ctgf als biomarker, therapeutisches und diagnostisches ziel |